A good response rate to recombinant erythropoietin alone may be expected in selected myelodysplastic patients. A preliminary clinical study

European Journal of Haematology

Volumn 56, Issue 1-2, 1996, Pages 7-11

  Di Raimondo, F ^a,b   Longo, G ^a   Cacciola Jr , E ^a   Milone, G ^a   Palumbo, G A ^a   Cacciola, R R ^a   Alessi, M ^a   Giustolisi, R ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b Divisione Ematologia Oncologia Pediatrica   (Italy)

Author keywords

EPO; MDS; Selective criteria

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; MALE; MYELODYSPLASIA; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029995063     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1996.tb00286.x     Document Type: Article

References (20)

1. BENNET M, CATOVSKY D, DANIEL MT, et al. The French-American-British (FAB) co-operative group. Br J Haematol 1982: 51: 189-199.
2. ESCHBACH JW, EGRIE JC, DOWNING MR, BROWNE JK, ADAMSON JW. Correction of the anemia of end-stage renal disease with rhEpo: results of a combined phase I and II clinical trial. N Engl J Med 1987: 316: 73-78.
3. BESSHO M, JINNAI I, MATSUDA A. Improvement of anemia by recombinant erythropoietin in patients with myelodysplastic syndromes and aplastic anemia. Int J Cell Cloning 1990: 8: 445-458.
4. BOWEN D, CULLIGAN D, JACOBS A. The treatment of anaemia in the myelodysplastic syndromes with recombinant human erythropoietin. Br J Haematol 1991: 77: 419-423.
5. STEIN RS, ABELS RI, KRANZ SB. Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes. Blood 1991: 78: 1658-1663.
6. SCHOUTEN HC, VELLENGA E, VAN RHENEN DJ, DE WOLF JTM, COPPENS PJW, BLIJHAM GH. Recombinant human erythropoietin in patients with myelodysplastic syndromes. Leukemia 1991: 5: 432-436.
7. KURZROCK R, TALPAZ M, ESTEY E, O'BRIEN S, ESTROV Z, GUTTERMAN JU. Erythropoietin treatment in patients with myelodysplastic syndrome and aplastic anemia. Leukemia 1991: 5: 985-990.
8. HELLSTRÖM E, BIRGEGARD G, LOCKNER D, HELMERS C, OST A, WIDE L. Treatment of myelodysplastic syndromes with recombinant human erythropoietin. Eur J Haematol 1991: 47: 355-360.
9. CAZZOLA M, PONCHIO L, BEGUIN Y, et al. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial. Blood 1992: 79: 29-37.
10. VERHOEF GEG, ZACHÈE P, FERRANT A, et al. Recombinant human erythropoietin for the treatment of anemia in the myelodysplastic syndromes: a clinical and erythrokinetic assessment. Ann Hematol 1992: 64: 16-21.
11. RAFANELLI D, GROSSI A, LONGO G, et al. Recombinant human erythropoietin for treatment of myelodysplastic syndromes. Leukemia 1992: 6: 323-327.
12. SANZ GF, SANZ MA, VALLESPI T, et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 1989: 74: 395-408.
13. AUL C, GATTERMANN N, HEYLL A, GERMING U, DERIGS G, SCHNEIDER W. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposal for an improved scoring system. Leukemia 1992: 6: 52-59.
14. HELLSTROM-LINDBERG E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 1995: 89: 67-71.
15. BAER AN, DESSYPRIS EN, GOLDWASSER E, KRANTZ SB. Blunted erythropoietin response to anemia in rheumatoid arthritis. Br J Haematol 1987: 66: 559-564.
16. LONGO G, MILONE G, CACCIOLA RR, CACCIOLA E JR, ASSISI A, MARRA G. High response rate to rhEpo in selected myelodysplastic patients. Abstr 24th Congress Int Soc Haematol, London, Aug 23-27, 1992 (abstr 681).
17. STENKE L, WALVIK J, CELSING F, HAST R. Prediction of response to treatment with human recombinant erythropoietin in myelodysplastic syndromes. Leukemia 1993: 7: 1324-1327.
18. MITTELMAN M, FLORU S, DJALDETTI M. Subcutanous erythropoietin for treatment of refractory anemia in hematologic disorders. Blood 1992: 80: 841-843.
19. VERHOEF GEG, ZACHEE P, DEMUYNCK H, et al. Measurement of serum cytokines levels in patients with myelodysplastic syndromes. Abstr 24th Congress Int Soc Haematol 1368, 1992.
20. MUSTO P, MATERA R, MINERVINI MM, et al. Low serum level of tumor necrosis factor and interleukin-1 β in myelodysplastic syndromes responsive to recombinant erythropoietin. Hematologica 1994: 79: 265-268.